Liquidia (LQDA) vs SELLAS Life Sciences Group (SLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed Liquidia (LQDA) over the past year, gaining 483.4% versus a gain of 16.4%. Over five years, LQDA leads with a +775.6% price change compared with +28.1% for SLS. Liquidia is the larger company by market cap ($2.51 billion vs $2.27 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LQDA | SLS |
|---|---|---|
| Share price | $28.02 | $11.26 |
| Market cap | $2.51B | $2.27B |
| 1-day change | +5.02% | -0.44% |
| YTD return | -18.76% | +198.67% |
| 1-year return | +16.36% | +483.42% |
| 5-year return | +775.63% | +28.09% |
| P/E ratio (TTM) | 20.16 | — |
| Forward P/E | 11.66 | — |
| EPS (TTM) | $1.39 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $93.61 | $15.88 |
| 52-week low | $21.94 | $1.39 |
| Distance from 52-week high | -70.07% | -29.09% |
| Analyst consensus | buy | none |
| Avg. price target upside | +77.27% | +188.63% |
| Average volume | 2.40M | 6.56M |
| Shares outstanding | 89.51M | 201.95M |
| Employees | 216 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed LQDA by 467.1 percentage points over the past year.
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
LQDA vs SLS FAQ
Which is bigger, Liquidia or SELLAS Life Sciences Group?
Liquidia (LQDA) is larger, with a market capitalization of $2.51B compared with $2.27B for SELLAS Life Sciences Group (SLS).
Which stock has performed better over the past year, LQDA or SLS?
SLS returned +483.42% over the past 12 months, compared with +16.36% for LQDA (price return, excluding dividends). Past performance does not predict future results.
Are Liquidia and SELLAS Life Sciences Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.